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Abstract
Multiple models of human metabolism have been reconstructed, but each represents only a subset
of our knowledge. Here we describe Recon 2, a community-driven, consensus ‘metabolic
reconstruction’, which is the most comprehensive representation of human metabolism that is
applicable to computational modeling. Compared with its predecessors, the reconstruction has
improved topological and functional features, including ~2× more reactions and ~1.7× more
unique metabolites. Using Recon 2 we predicted changes in metabolite biomarkers for 49 inborn
errors of metabolism with 77% accuracy when compared to experimental data. Mapping
metabolomic data and drug information onto Recon 2 demonstrates its potential for integrating
and analyzing diverse data types. Using protein expression data, we automatically generated a
compendium of 65 cell type–specific models, providing a basis for manual curation or
investigation of cell-specific metabolic properties. Recon 2 will facilitate many future biomedical
studies and is freely available at http://humanmetabolism.org/.
An understanding of metabolism is fundamental to comprehending the phenotypic behavior
of all living organisms, including humans, where metabolism is integral to health and is
involved in much of human disease. High quality, genome-scale ‘metabolic reconstructions’
are at the heart of bottom-up systems biology analyses and represent the entire network of
metabolic reactions that a given organism is known to exhibit1. The metabolic-network
reconstruction procedure is now well-established2 and has been applied to a growing
number of model organisms3. Metabolic reconstructions allow for the conversion of
biological knowledge into a mathematical format and the subsequent computation of
physiological states1,4,5 to address a variety of scientific and applied questions3,6.
Reconstructions enable network-wide mechanistic investigations of the genotype-phenotype
relationship. A high-quality reconstruction of the metabolic network is thus of interest to the
community of researchers focused on the systems biology of metabolism of a target
organism.
Of the reconstructions of human metabolism that have appeared to date, perhaps the most
widely used is Recon 1 (ref. 7), which represents a knowledgebase and has also been
converted into many predictive models. These models have been used for various
biomedical applications, including the prediction of biomarkers for inborn errors of
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metabolism (IEMs)8, cancer drug targets9,10 and off-target drug effects11. Moreover, they
have been used to evaluate missing metabolic functions systematically12,13 and to model
host-microbe interactions14,15. These studies demonstrated the potential of metabolic
modeling to advance understanding of human metabolism in health and disease.
Various reconstructions of the human metabolic network exist, with only partially
overlapping content (ref. 16 and Supplementary Note 1). In addition to Recon 1, a global
human metabolic reconstruction, EHMN (Edinburgh Human Metabolic Network)17, has
also been published. Manually curated cell type–specific reconstructions are also available,
including the comprehensive reconstruction of human hepatocytes, HepatoNet1 (ref. 18), a
small intestinal enterocyte reconstruction19 and other metabolic models for macrophages14,
hepatocytes20 and kidney cells11. Moreover, a module for Recon 1 that models acylcarnitine
and fatty-acid oxidation (Ac-FAO) has recently been published8, which includes the
metabolic surroundings of many biomarkers measured in the worldwide newborn screening
program21. Recon 1 has also been used for the automated generation of cell-specific and
tissue-specific models using various ‘omics’ data sets22,23, and to generate metabolic
reconstructions semiautomatically for other mammals, such as the mouse24.
It is clear that ‘competing’ (that is, different) reconstructions and reconstruction approaches
coexist, but all have the common goal of providing an up-to-date, comprehensive and high-
quality reconstruction, either at the global or cell-specific scale. Rather than continuing to
duplicate efforts, a substantial fraction of the community has pooled resources to generate a
consensus human metabolic reconstruction from many of the sources cited above.
Here we describe Recon 2, a community-driven expansion of the global human metabolic
reconstruction, Recon 1. Much of this expansion was performed at reconstruction
‘jamboree’ meetings25, focused events at which domain experts apply their knowledge to
refine and consolidate biochemical knowledge from existing reconstructions and published
literature. Members of the Saccharomyces cerevisiae26,27 and Salmonella typhimurium LT2
(ref. 28) communities have used such a jamboree approach. The jamboree events provided
the opportunity to establish common standards (and suitable links to other databases) for the
consensus reconstruction and the format of its content, to simplify its reuse and extension,
and to increase its transparency and commitment to its development via participation of
many stakeholders in the community. Here we also demonstrate the improved predictive
capability of Recon 2 over that of its predecessor. We mapped exometabolomic data29 onto
Recon 2 and used proteomics data to generate cell type–specific metabolic models, which
we then investigated for their functional properties.
RESULTS
Reconstruction approach
To assemble Recon 2, we added metabolic information present in four different resources
(EHMN17, HepatoNet1 (ref. 18), Ac-FAO module8 and the human small intestinal
enterocyte reconstruction19) to the content of Recon 1 following a step-wise process (Fig.
1). We added more than 370 transport and exchange reactions, based on a review of
literature. We applied unambiguous third-party identifiers for cellular compartments,
metabolites, enzymes and reactions. We mapped the content from the DrugBank30 database,
which lists experimental and US Food and Drug Administration-approved drugs, to
individual enzymes and reactions. Ninety-five percent of metabolic reactions were mass-
balanced and charge-balanced5,31 (Supplementary Table 1), except for those containing
metabolites that have either no defined chemical formula or a generic formula. We tested
Recon 2 for self-consistency2, a process that included gap analysis2 and leak tests32.
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Benchmarking Recon 2 against Recon 1
Recon 2 accounts for 1,789 enzyme-encoding genes, 7,440 reactions and 2,626 unique
metabolites distributed over eight cellular compartments, which is a large increase in
comprehensiveness relative to Recon 1 (Table 1). Such an increase in scope does not
necessarily constitute an improvement in utility over the previous version: expanding the
reconstruction to resolve existing gaps and dead-end metabolites may introduce additional
gaps and dead ends elsewhere. To demonstrate an improvement of the network, both
coverage and functional improvements must be considered.
To quantify the overall improvements achieved through the community-driven expansion
and refinement in the global human metabolic reconstruction, we compared the information
coverage, topological and functional properties of Recon 2 with those of Recon 1 (Table 1).
The reaction content was almost doubled, much of which belonged to one of the nine new
pathways (Fig. 2). Moreover, 62% (61/99) of the existing pathways have been expanded in
Recon 2, and reaction coverage in 29 pathways, accounting for 16.5% (1,231/7,440) of the
reactions, remained unchanged. A total of 307 dead-end metabolites (metabolites that are
either only produced or only consumed in the reconstruction) from Recon 1 were resolved in
Recon 2, whereas 32 remained as participants in only one reaction. As a result of the
expansion, 1,144 new dead-end metabolites, mostly from EHMN, were introduced. These
will need to be connected to the rest of the network in subsequent efforts. Blocked reactions
cannot carry a nonzero flux in any steady-state condition because they contain one or more
dead-end metabolites or are in a linear pathway with such reactions. The expanded coverage
of metabolic information resolved 827 blocked reactions present in Recon 1, and 443
blocked reactions remained (Table 1). The number of remaining and new blocked reactions
and dead-end metabolites highlights that this current update is not intended to be the final
compendium of human metabolism, but it is a major advance over Recon 1 and represents
our current, continually evolving knowledge.
A metabolic task is defined as a nonzero flux through a reaction or through a pathway
leading to the production of a metabolite B from a metabolite A. Examples of such tasks
include the synthesis of all known precursors to produce a cell (biomass reaction;
Supplementary Note 2) and the generation of energy via oxidative phosphorylation or
fermentation (Supplementary Table 2). A total of 354 metabolic tasks were defined.
Although a particular cell type is not capable of fulfilling all these metabolic tasks, Recon 2
should be able to fulfill these tasks because it is a global metabolic reconstruction. Recon 2
carried a nonzero flux for all tasks, compared with Recon 1, which achieved this
functionality for only 83% of the tasks (Table 1).
To benchmark the models derived from both reconstructions against an independent data set,
we used a manually assembled compendium of IEMs8 as a gold standard. This compendium
accounts for 330 IEMs, such as phenylketonuria and orotic aciduria, along with their known
metabolite biomarkers. As Recon 2 captured more metabolic genes, more IEMs could be
mapped (Table 1). In Recon 2, almost all of the mapped IEMs affected the reaction activity,
as no complementary isoenzymes are known for the absent enzymes (consistent with their
occurrence as IEMs). We compared the predictive potential of Recon 2 and Recon 1 for
associated biomarkers for the mapped IEMs (Fig. 3), in a process analogous to gene-deletion
studies in microbial modeling. Recon 2 predicted 54 reported biomarkers for 49 different
IEMs, with an accuracy of 77%. The coverage of predicted biomarkers and the accuracy was
much lower for Recon 1, with 31 reported biomarkers for 29 IEMs and an accuracy of 63%
(Fig. 3). This comparison demonstrates that the increased scope of Recon 2 led to a higher
coverage of IEM-related biomarkers mapped and to an increase in predictive power.
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Based on the accurate predictive capability of Recon 2 for biomarkers and for the metabolic
tasks, the benchmarking demonstrated an increase in both scope and predictive accuracy of
Recon 2 relative to its predecessor.
Recon 2 captures the majority of known exometabolites
Recon 2 accounts for 642 extracellular metabolites, which should be found in cell culture
medium and in biofluids such as plasma and urine. When comparing these extracellular
metabolites with a reported subset of a cancer exometabolome33 consisting of 140
metabolites, the majority of the metabolites were indeed present in the extracellular
compartment (Fig. 4a and Supplementary Table 3). Using a flux variability analysis34, we
predicted in silico the uptake and release profile of Recon 2. Recon 2 had high sensitivity in
predicting correctly the uptake and release for 91 metabolites (sensitivity values of 0.92 and
0.94, respectively; Supplementary Table 3). However, the capability of Recon 2 to predict
true negatives (that is, metabolites that cannot be taken up or released) was very low. For
instance, 14% (13/91) of the metabolites could not be released by any of the tested cancer
cell lines, whereas all but one metabolite was released in silico. As Recon 2 represents the
combined metabolic capability of all cells in the human body, not just of neoplastic cells, the
low sensitivity is expected. The mismatches could be used to guide the assembly of cancer-
specific metabolic models or to refine an existing cancer metabolic model9. It is noteworthy
that Recon 2 contains many more extracellular metabolites (551), which were not seen in the
experimental exometabolome, presumably in part because of the targeted liquid
chromatography–tandem mass spectrometry method used33, as more than 1,000 metabolite
peaks can easily be observed in human serum35.
We also compared the Recon 2 exometabolome and the metabolites reported in the Human
Metabolome Database (HMDB)36 as being detectable in biofluids (Fig. 4b). Biofluid
information could be found for about half of the metabolites in Recon 2 identified in the
HMDB. About 44% of these metabolites were also present in the extracellular compartment,
indicating that there are still some transport and metabolic routes missing in Recon 2.
In summary, Recon 2 captured many of the reported exometabolites and biofluid
metabolites, illustrating its comprehensiveness and the value of annotating with multiple
metabolite identifiers, permitting the integration of data from many sources.
Generation of draft, cell type–specific models
A metabolic reconstruction is unique to a genome, and thus to an organism, but condition-
specific constraints can be applied to create a condition-specific model from the
reconstruction. Thus, one reconstruction can give rise to many models. We mapped
expression data from the Human Protein Atlas37 for 65 cell types, capturing information for
25% (451/1,789) of the unique gene products in Recon 2 (Supplementary Fig. 1). These data
were used together with a published algorithm5,38 to generate 65 draft cell type–specific
metabolic models consisting of 2,426 ± 467 reactions (± s.d.) and 1,262 ± 204 transcripts
(Fig. 5). Of the 593 core reactions present in all cell-type models, more than half of them
were transport reactions (Supplementary Table 4). Furthermore, 33% (2,463/7,440) of the
Recon 2 reactions appeared in none of the cell-type models, with almost 40% (968/2,463) of
those belonging to the subsystem ‘lipids’ (Supplementary Fig. 2). Based on the cell type–
specific models, 26% (457/1,789) of the genes in Recon 2 represent the core genes (that is,
they were found in all cell type–specific models), and 58% of the genes were part of two or
more models. Only 32 genes were specific to a particular cell type–specific model. The
remaining 14% (245/1,789) of the genes were not captured by any cell type–specific model.
The glandular-cell models were highly correlated based on presence and absence of genes
and reactions, whereas epithelial-cell models were less correlated (Supplementary Figs. 3,4).
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Overall, we observed higher correlation on the subsystems level with the ‘transport’
subsystem being the most correlated one, highlighting the importance of nutrient uptake and
secretion for cellular function (Supplementary Figs. 3,5).
The automatically generated hepatocyte model captured 61% (1,109/1,823) of the reactions
present in a published hepatocyte model20, whereas 64% (1,932/3,041) of this model’s
reactions were not in the published model. When comparing our draft hepatocyte model
with the published hepatocyte model, HepatoNet1 (ref. 18), 1,098 reactions were present in
both, whereas 64% (1,943/3,041) were unique to our model and 57% (1,441/2,539) of
reactions were unique to HepatoNet1. Such discrepancies between our draft model and the
published cell-type models may serve as an indication of areas of attention for subsequent
manual curation and assessment.
We investigated the metabolic tasks that each cell type–specific model can perform. On
average, the cell type–specific models had nonzero flux for 174 ± 32 of 354 metabolic tasks.
Thirty-one metabolic tasks could be carried out by all such models, many of which tested
different aspects of amino-acid metabolism, and 44 metabolic tasks had a zero flux for all
models. Of all of these models, only the hepatocyte model could generate urea, via the urea
cycle, which is consistent with current knowledge. Small intestinal enterocytes are also
capable of urea synthesis but are currently not captured by the Human Protein Atlas37.
Notably, 25% (16/65) of the models had a nonzero flux through the biomass reaction, which
means that these models contain all necessary reactions either to take up or synthesize all the
precursors defined in the biomass reaction.
Recon 2 includes mappings of drug actions to enzymes
Recon 2 includes 2,657 metabolic enzymes and 1,052 enzymatic complexes, many of which
are known drug targets. We queried DrugBank30, a comprehensive resource that includes
drug-to-enzyme mappings for >6,000 small-molecule and peptide or protein drugs, to allow
drugs (and their actions) to be mapped to the enzymes of Recon 2. We found that 1,290
drugs were mapped to 308 enzyme and enzymatic complexes. This equated to 3,168 drug-
enzyme or drug-complex interactions, of which 841 were specified as inhibitory. These
mappings are included in both the global reconstruction and the cell type–specific models,
providing a starting point for the simulation of drug actions with both constraint-based and
kinetic modeling1,39,40.
DISCUSSION
Our results illustrate that (i) Recon 2 is a comprehensive metabolic resource and serves as an
effective predictive model; (ii) mapping of exometabolomic data onto Recon 2 provides a
starting point for further iterative expansion and refinement; (iii) protein expression data and
Recon 2 can be used to generate draft cell type–specific metabolic models; and (iv)
comparative analysis of cell type–specific models provides insight into alternate metabolic
strategies.
The metabolic reconstruction process is inherently iterative, as increasing biochemical and
genomic knowledge is generated about the target organism over time. This calls for periodic
updates and expansion in the coverage and content of a reconstruction2; thus we adopted the
‘Recon 1’ and ‘Recon 2’ naming convention in analogy with the ‘build X’ convention for the
assembly of the human genome sequence and similar conventions used in the naming of
iteratively released metabolic reconstructions in yeast27. The published resources for human
metabolism differ in syntax and content; for instance, a comparison of five different
resources revealed that only a small number of overlapping reactions were present in all
resources (ref. 16 and Supplementary Note 1). These discrepancies make it difficult to
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compare and combine metabolic reconstructions. We overcame this issue by manually
curating overlapping entries. The presented consensus reconstruction of human metabolism
is fully semantically annotated41 with references to persistent and publicly available
chemical and gene databases, unambiguously identifying its components and increasing its
applicability for third-party users (including automated processing by software). Moreover,
the work expanded beyond combining existing resources, by adding transport and
absorption reactions known to occur in epithelial cells of the gastrointestinal tract and the
renal tubules. Drug information was mapped from DrugBank30, providing a comprehensive
starting point to investigate off-target effects of drugs11 or to obtain information on known
drugs for drug target predictions studies9.
We improved the predictive potential of Recon 2 through the addition of new content. The
number of IEMs that Recon 2 captured and the accurate prediction of known biomarkers
(Fig. 3) demonstrate the substantial functional advancement achieved through the expansion
and refinement. We illustrated the potential of the constraint-based modeling approach by
generating a global model, not tailored to a particular application, which can nonetheless
predict accurately many distinct biomarkers for many IEMs. In addition, Recon 2 also
predicted some previously undescribed biomarkers, which have not yet been measured8.
With the increasing sophistication of targeted metabolomic approaches42, biomarker
predictions may help to guide such analyses. Additionally, large cohort studies have started
to connect genotype with metabotype43. As Recon 2 captures most of the measured
metabolites, it provides a resource for investigating the connection between genotype and
metabotype and ultimately phenotypes based on these data.
We mapped two large-scale exometabolome resources to Recon 2, showing that Recon 2
captures most of the exometabolites and biofluid metabolites reported therein. Although this
illustrated the comprehensiveness of the reconstruction, it also highlighted that the
information content in the reconstruction is still not complete. Many algorithms exist that
may assist in proposing missing metabolic and transport reactions in Recon 2 and thus aid
subsequent manual curation (Supplementary Note 3)12,13,44. It is also clear that reported
biofluid metabolites36 might be of dietary and/or microbial origin, as the mammalian gut
microbiota has been found to affect blood composition45 and metabolism46 substantially. To
determine the origin of the biofluid metabolites, a comprehensive computational model
accounting for microbial metabolism, human metabolism and dietary composition is needed.
Recon 1 has been used together with omics data to generate comprehensive sets of draft cell
type–specific metabolic reconstructions23,38. We mapped data from the Human Protein
Atlas37 onto Recon 2 to generate 65 cell type–specific metabolic models automatically.
Although protein expression data were available for only one-quarter of the Recon 2 gene
products, to our surprise the draft cell type–specific models contained many reactions and
genes (Fig. 5). The size of many published cell type–specific models, which have been at
least in part generated automatically, is comparable23,37. In a comparison of our
automatically generated hepatocyte model with two published models18,20, we found
reasonable overlap, even though these models were assembled using different methods and
information. Our automatically generated hepatocyte model contained alternate reactions,
which reflect the proteomic input data and the algorithm used. For instance, the protein
expression data were limited to those that had a high confidence level, but by including
lower-confidence expression data, combined with a weighting scheme, one may obtain
alternate draft models. Moreover, the algorithmic approach currently does not consider
transcriptional regulation, thermodynamic constraints and the synthesis cost for each
enzyme and its building blocks. Ultimately, manual inspection and curation will be
necessary to obtain more versatile, comprehensive, predictive cell type–specific models.
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To assess the functionality of the automatically generated cell type–specific models, we
tested 354 metabolic tasks. One-quarter of the models could produce all defined biomass
precursors, thus enabling them to simulate cell growth. A review of literature revealed that
some of these cell types are indeed known to divide in vivo upon injury or induction by
specific growth factors. The protein expression data are generated in many cases on tissue
biopsies. The growth capabilities could not have been determined from the omics data alone,
and this highlights the importance of computational modeling to analyze experimental data.
Moreover, the metabolic activity profile, combined with the set of active exchange reactions,
could be compared with cell type–specific literature to evaluate the correctness of the
metabolic content of each model and to refine the models by enabling or disabling additional
tasks, exchange reactions and metabolic content.
We anticipate that, as a result of the improvements over its predecessor, Recon 2 will be
widely used and will enable the exploration of new frontiers in research in human
metabolism and its role in health and disease. The global model is available via a database at
http://humanmetabolism.org/, in SBML format at Biomodels (http://identifiers.org/
biomodels.db/MODEL1109130000) and as Supplementary Data 1.
ONLINE METHODS
Reconstruction approach
The reconstruction of the expanded and refined global human metabolic network, Recon 2,
was performed in multiple stages. Intermediate versions of Recon 2 are referred to as ‘Recon
1.x’.
Jamboree work—The jamboree meetings were used to discuss strategies combining the
content of the two reconstructions and the required quality control of the finished consensus.
The strategy was to start with the compartmentalized Recon 1 reconstruction and
incrementally add reactions from the EHMN reconstruction.
Initially, automated approaches31 were applied to Recon 1 (ref. 7) and the EHMN17 to solve
the problem of inconsistent naming of the components (compartments, metabolites, genes
and reactions). The remaining components that could not be automatically matched to
existing database entries were manually annotated during the jamboree meetings. Cellular
compartments were annotated with Gene Ontology (GO) terms. Metabolites were annotated
with terms from the resources Chemical Entities of Biological Interest (ChEBI), Kyoto
Encyclopedia of Genes and Genomes (KEGG) Compound, PubChem Compound and
HMDB36, and also IUPAC International Chemical Identifier (InChI) terms where possible.
Where metabolites were not present in any existing data resources, many were submitted as
new entries to ChEBI. Enzymes were annotated with Enzyme Classification (EC) terms, US
National Center for Biotechnology Information (NCBI) Gene identifiers and UniProt terms.
The jamboree meetings also focused on manual curation of the reconstruction content.
Reactions were curator-validated and annotated with PubMed literature references,
standardized GO evidence codes (Supplementary Table 6) and a confidence scoring system
ranging from 0 (no evidence) to 4 (biochemical evidence)2. Metabolites and enzymes were
assigned to appropriate cellular compartments. Metabolic reactions were checked to ensure
correct stoichiometry, irreversibility, correct assignment of gene association and enzyme
rules, and mass and charge balancing, and appropriate transport reactions were added.
Post-jamboree work—For reactions that occurred in both Recon 1 and EHMN, the co-
occurrence was considered to be evidence for their inclusion in Recon 1.x. The jamboree
teams had manually evaluated reactions from Recon 1, and reactions unique to the
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compartmentalized EHMN were added to Recon 1.x only if they were mass- and charge-
balanced. The charge state of metabolites was calculated at an assumed pH of 7.2. Reactions
were mass- and charge-balanced where possible, as defined in Recon 1. Where additional
metabolites and reactions were added from sources such as EHMN, the SuBliMinaL
Toolbox31 and COBRA Toolbox5 were used to apply mass and charge balancing. In cases
where reactions contained ‘generic’ compounds (containing –R and –X groups), which were
used to represent a set of specific compounds to decomplexify the reconstruction, mass and
charge balancing was not possible. An investigation into thermodynamic consistency of
Recon 1 reactions47 proposed changes to a small subset of reactions, which were also
incorporated. We also updated the gene list based on changes introduced from build 35 to
build 37, which includes the removal or replacement of obsolete gene entries.
Subsequently, the Recon 1.x content was extended to account for the content in the
published HepatoNet1 (ref. 18) reconstruction. The same procedure for converting
HepatoNet1 to the syntax of Recon 1.x was used as described above. As HepatoNet1 is a
pruned and cell-specific stoichiometric model, some conventions were different from that in
Recon 1.x. Most importantly, the implementation of lipids as some specific pools with fixed
fatty-acid distributions was incompatible with the flexible and less specified R system in
Recon 1.x, and therefore the lipid reactions were excluded from the merging process.
HepatoNet1 accounts for multiple extracellular compartments. For simplicity, all of the
HepatoNet1 extracellular metabolites and reactions were assumed to be present in a single
common extracellular compartment, following the convention of Recon 1.
Content from both the recently published acylcarnitine–fatty acid oxidation module8 and the
metabolic reconstruction for human small intestinal enterocytes19 were also added to Recon
1.x. The latter accounts for two extra-cellular compartments (luminal and blood side).
Again, a single extracellular compartment was assumed.
As a final step of expanding the content of the global human metabolic reconstruction,
thorough literature research was performed to identify missing transport and absorption
reactions in Recon 1.x. The reconstruction of this module was performed as described
previously2.
The reconstruction assembly and conversion to a mathematical model was done using
rBioNet48. The uniqueness of reactions in Recon 1.x was determined, and multiple rounds of
self-consistency testing and functional assessment of the model performed using established
procedures2, which included gap analysis2, leak tests32 and a functional analysis.
The resulting reconstruction was finalized and named Recon 2.
Leak analysis
A model of Recon 2 was used for the leak analysis, in which all unbalanced reactions were
considered inactive by constraining their lower and upper bound flux bounds to zero. The
test of mass leaks was performed with a simulation procedure defined in the tutorial of
FASIMU32, by looking for steady-state flux distributions that either (i) consume no
substrates and generate an output or (ii) consume substrates but do not generate products.
The flux distributions representing a leak were analyzed manually to identify causative
unbalanced reactions. After balancing or deleting the corresponding reaction(s), the test was
repeated until no additional leaks were observed. In all simulations with Recon 1 and Recon
2, all metabolites with defined exchange reactions could be taken up and secreted. Reaction
constraints applied to the leak-free Recon 2 model that was used for all computations in this
study are listed in Supplementary Table 7.
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Topological analysis
Performing flux variability analysis34, while permitting constrained uptake and secretion of
all metabolites with defined exchange reactions has been defined, allowed the identification
of blocked reactions in Recon 1 and Recon 2, that is, reactions that could not carry any
nonzero flux under this simulation condition. Dead-end metabolites were identified as
described previously2. Compound participation was calculated as described by previously1
(Supplementary Note 4).
Functional characterization of Recon 1 and Recon 2
The metabolic capacity of the network was demonstrated by testing nonzero flux values for
354 metabolic tasks, which were based on Recon 1 and ref. 19. For each of the simulations a
steady-state flux distribution was calculated. Each metabolic task was optimized
individually by choosing the corresponding reaction in either Recon 1 or Recon 2, if present,
as objective function and maximized the flux through the reaction (see Supplementary Table
2).
Mapping the compendium of inborn errors of metabolism and predicting biomarkers
The compendium of IEMs8 contains information about causative genes and known
biomarkers for 330 distinct IEMs. Using gene-reaction associations, the IEMs were mapped
onto Recon 1 and Recon 2. A gene-associated reaction was affected if no isoenzyme existed
that was not known to cause an IEM. To predict biomarkers for each IEM affecting one or
more reaction, the method reported in ref. 49 was followed. Changes in biomarkers resulting
from an IEM were compared with reported biomarkers for each IEM. A Fisher’s exact test
was applied to compute the hypergeometic P value. This analysis was performed for Recon
1 and Recon 2. Mapped IEMs are listed in Supplementary Table 5.
Cancer exometabolome mapping
Information related to a cancer exome-tabolome33, which reported consumed and secreted
compounds in the culture medium, was manually mapped to the metabolites of Recon 2
(Supplementary Table 3). Flux variability analysis was performed on the exchange
reactions, and the uptake-secretion capability was compared with reported consumption and
secretion capability of the cancer cells.
Biofluid metabolome mapping
Information about the biofluid location of metabolites was obtained from the MNDB
(version August 2012)36. Mapping was performed through HMDB identifiers, which were
recorded during the reconstruction process.
Protein expression data mapping
Protein expression data were downloaded from the Human Protein Atlas37 in May 2012 and
Ensembl identifiers were mapped onto Recon 2 gene products. Gene products with
moderate/medium and strong/high levels of expression were assumed to be present, and all
others were assumed to be absent. Gene products without data in a cell type were assumed to
be absent.
Generation of a draft cell type–specific model compendium
For each cell type, the presence and absence information from the protein expression data
was used as input for the MinMax algorithm38, which was implemented in the COBRA
Toolbox5. The biomass reaction and a reaction representing ATP hydrolysis were
subsequently added to each model. The IEM compendium was mapped onto each cell type–
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specific draft model as described above. For each model, its capability to perform the
defined metabolic tasks was tested.
SBML models
Recon 2 is available in the Systems Biology Markup Language format (SBML)50, which is
compliant with the Minimal Information Required In the Annotation of Models (MIRIAM)
standard41 at http://humanmetabolism.org/, Biomodels (http://identifiers.org/biomodels.db/
MODEL1109130000) and as Supplementary Data 1 (which also contains all derived cell
type– specific versions). The programming library libAnnotationSBML51 was used to apply
unified cross-references in the form of MIRIAM identifiers to most components in the
models. Systems Biology Ontology (SBO) terms were applied to specify metabolites,
polypeptides and protein complexes, and to make the distinction between biochemical and
transport reactions.
DrugBank data mapping
DrugBank30 was queried via its XML file download, and enzymes were mapped to their
equivalent in Recon 2 by consideration of both UniProt identifiers and specified intracellular
compartmentalization. Drugs (and their actions) were mapped to enzymes and included in
the distributed SBML50 versions of the Recon 2 models as annotations on enzyme species.
Software
All computations were carried out in the Matlab programming environment (MathWorks,
Inc.) using the COBRA Toolbox5 and Tomlab cplex as the linear programming solver
(TomOpt, Inc.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Overview of the community-driven reconstruction approach to assemble Recon 2. Comp.
EHMN, compartmentalized EHMN; and hs_sIEC611, small intestinal enterocyte
reconstruction.
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Figure 2.
Pathway coverage in Recon 1 and Recon 2. Only pathways with added reaction content in
Recon 2 are shown. The 29 pathways that have identical reaction content in both
reconstructions are not shown.
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Figure 3.
Predicted biomarkers for IEMs. (a) Comparison of the prediction accuracy of Recon 1 and
Recon 2 against the gold standard8. (b) Correct and incorrect predictions. IEMs and
biomarkers are sorted by subsystem. Bright yellow, amino-acid metabolism; green, central
metabolism; blue, hormones; yellow, lipid metabolism; pink, nucleotide metabolism; lilac,
vitamin and cofactor metabolism. Blue and red shading corresponds to predicted increase
and decrease in biomarker, respectively. Blue and red lines represent reported increase and
decrease of the biomarker in plasma, respectively. 34dhphe, 3,4-dihydroxy-L-phenylalanine;
3mlda, 3-methylimidazoleacetic acid; 5htrp, 5-hydroxy-L-tryptophan; bhb, (R)-3-
hydroxybutanoate; tetdec2crn, tetradecadienoyl carnitine; tetdece1crn, tetradecenoyl
carnitine. (See Supplementary Table 5 for complete names of the IEMs.)
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Figure 4.
Comparison of metabolomic data with the extracellular metabolites present in Recon 2
metabolites. (a) Comparison with the cancer exometabolome33 (see Supplementary Table 3
for a breakdown of the 18 cancer exometabolites that are absent from Recon 2, the 31 for
which no exchange reaction is present, and the 91 for which uptake or release profile
comparisons could be performed). (b) Comparison with the HMDB36 (see Supplementary
Fig. 6).
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Figure 5.
Summary properties of the 65 draft cell type–specific models. (a) Distribution of reaction
(left) and genes (right) across the models. (b) The protein expression data captured proteins
from all subsystems almost evenly. In contrast, most of reactions in the core reaction set,
consisting of 593 reactions, belonged to the transport subsystem. The second largest
subsystem in Recon 2, lipid metabolism, represented only a small fraction of the core
reaction set.
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Table 1
Comparison of major features of Recon 2 and its predecessor Recon 1
Property Recon 1 Recon 2
Total number of reactions 3,744 7,440
Total number of metabolites 2,766 5,063
Number of unique metabolites 1,509 2,626
Number of metabolites in extracellular space 404 642
Number of metabolites in cytoplasm 995 1,878
Number of metabolites in mitochondrion 393 754
Number of metabolites in nucleus 95 165
Number of metabolites in endoplasmic reticulum 235 570
Number of metabolites in peroxisome 143 435
Number of metabolites in lysosome 217 302
Number of metabolites in Golgi apparatus 284 317
Number of transcripts 1,905 2,194
Number of unique genes 1,496 1,789
Number of subsystems 90a 99
Number of blocked reactions (% of all reactions) 1,270 (34%) 1,603 (22%)
Number of dead-end metabolites 339b 1,176b
Size of Sc (m; n) 2,766; 3,744 5,063; 7,440
Number of linearly independent mass balances 1,070 2,774
Sparsity (% of nonzero entries in S) 0.1385 0.0837
Number of accomplished metabolic tasks 294 354
Mapped IEMs (% of all IEMs) 233 (71%) 248 (76%)
Number of unique genes causing IEMs 255 272
Number of IEMs affecting metabolic tasks (% of effective IEMs) 71 (36%) 98 (44%)
a
Based on the subsystems categories defined for Recon 2.
bAll but 32 dead-end metabolites Recon 1 have been resolved in Recon 2. Addition of new reactions and pathways (mostly from EHMN) led to the
introduction of new dead-end metabolites, which was a starting point for subsequent curation efforts.
c
The stoichiometric matrix (S) consists of m rows, each representing a single metabolite and n columns, each representing a single reaction. When
a metabolite participates in a reaction the corresponding cell in the S matrix has a negative nonzero entry for substrates and a positive nonzero entry
for products.
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